Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chao, Liu, Ruiqi, Wang, Bojun, Lian, Jie, Yao, Yang, Sun, Haoxiu, Zhang, Chunhui, Fang, Lin, Guan, Xin, Shi, Jiaqi, Han, Shuling, Zhan, Fei, Luo, Shengnan, Yao, Yuanfei, Zheng, Tongsen, Zhang, Yanqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813395/
https://www.ncbi.nlm.nih.gov/pubmed/33462141
http://dx.doi.org/10.1136/jitc-2020-001895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813395/
https://www.ncbi.nlm.nih.gov/pubmed/33462141
http://dx.doi.org/10.1136/jitc-2020-001895

Ejemplares similares